Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Vertex Pharmaceuticals Incorporated. Vertex Pharmaceuticals Incorporated business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Vertex Pharmaceuticals Incorporated are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Vertex Pharmaceuticals Incorporated , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Vertex Pharmaceuticals Incorporated including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Vertex Pharmaceuticals Incorporated and all latest updates of the company are provided. The 2025 version of Vertex Pharmaceuticals Incorporated report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.
Chat on WhatsApp
